<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Pediatr</journal-id><journal-id journal-id-type="iso-abbrev">BMC Pediatr</journal-id><journal-id journal-id-type="pmc-domain-id">55</journal-id><journal-id journal-id-type="pmc-domain">bmcpedi</journal-id><journal-title-group><journal-title>BMC Pediatrics</journal-title></journal-title-group><issn pub-type="epub">1471-2431</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11542491</article-id><article-id pub-id-type="pmcid-ver">PMC11542491.1</article-id><article-id pub-id-type="pmcaid">11542491</article-id><article-id pub-id-type="pmcaiid">11542491</article-id><article-id pub-id-type="pmid">39511521</article-id><article-id pub-id-type="doi">10.1186/s12887-024-05206-y</article-id><article-id pub-id-type="publisher-id">5206</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Impact of chronic opioid use on acute health care utilization in children with IBD and arthritis: a retrospective cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Dagci</surname><given-names initials="AOB">Atiye O. Bilgic</given-names></name><address><email>olcaybilgicdagci@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="S">Shunzhou</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chang</surname><given-names initials="JC">Joyce C.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Grossman</surname><given-names initials="AB">Andrew B.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xiao</surname><given-names initials="R">Rui</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weiss</surname><given-names initials="PF">Pamela F.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01z7r7q48</institution-id><institution-id institution-id-type="GRID">grid.239552.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0680 8770</institution-id><institution>Division of Rheumatology, </institution><institution>Children&#8217;s Hospital of Philadelphia, </institution></institution-wrap>Philadelphia, PA USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00jmfr291</institution-id><institution-id institution-id-type="GRID">grid.214458.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7347</institution-id><institution>Division of Pediatric Rheumatology, </institution><institution>University of Michigan, </institution></institution-wrap>Ann Arbor, MI 48109 USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.25879.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8972</institution-id><institution>Department of Biostatistics, Epidemiology and Informatics, </institution><institution>University of Pennsylvania Perelman School of Medicine, </institution></institution-wrap>Philadelphia, PA USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00dvg7y05</institution-id><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution>Division of Immunology, </institution><institution>Boston Children&#8217;s Hospital and Harvard Medical School, </institution></institution-wrap>Boston, MA USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.25879.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8972</institution-id><institution>Department of Pediatrics, </institution><institution>University of Pennsylvania Perelman School of Medicine, </institution></institution-wrap>Philadelphia, USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01z7r7q48</institution-id><institution-id institution-id-type="GRID">grid.239552.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0680 8770</institution-id><institution>Division of Gastroenterology, Hepatology, and Nutrition, </institution><institution>Children&#8217;s Hospital of Philadelphia, </institution></institution-wrap>Philadelphia, PA USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.25879.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8972</institution-id><institution>Center for Pediatric Clinical Effectiveness, </institution><institution>University of Pennsylvania Perelman School of Medicine and Children&#8217;s Hospital of Philadelphia, </institution></institution-wrap>Philadelphia, PA USA </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>24</volume><issue-id pub-id-type="pmc-issue-id">452304</issue-id><elocation-id>711</elocation-id><history><date date-type="received"><day>26</day><month>11</month><year>2023</year></date><date date-type="accepted"><day>4</day><month>11</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>07</day><month>11</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-15 13:25:20.383"><day>15</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12887_2024_Article_5206.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Opioid use is non-trivial in children with inflammatory bowel disease (IBD) and arthritis, and options are limited for pain management. We aimed to determine the impacts of chronic opioid use on acute care utilization in children with both IBD and arthritis in United States.</p></sec><sec><title>Methods</title><p id="Par2">Participants less than 18 years of age with IBD and arthritis, with at least one year of continuous enrollment (no interruption of insurance for at least 1 year) and at least one pharmacy claim in the Truven Health MarketScan Claims and Encounter Database, were included in the study. The primary exposure was chronic opioid use. Chronic opioid users were matched to non-exposed controls. The primary outcome was acute healthcare utilization (total number of emergency department visits and hospitalizations within 12&#8211;24 months after the index date). The association between acute care utilization and chronic opioid use was assessed using a multivariable negative binomial regression model.</p></sec><sec><title>Results</title><p id="Par3">480 children with IBD and arthritis met inclusion criteria, out of which 59 (12.3%) met the criteria for chronic opioid exposure, and 46 of them had at least one year of follow-up. IRR (incidence rate ratio) of acute healthcare use for patients exposed to chronic opioid use was 1.7 higher than controls. Additionally, public insurance and having a chronic pain condition were independently and significantly associated with greater acute healthcare use.</p></sec><sec><title>Conclusion</title><p id="Par4">Chronic opioid use was significantly associated with greater acute health care utilization in children with IBD and arthritis than matched unexposed controls. Future investigation is warranted to determine if preferential use of non-opioid therapy for pain control can reduce acute healthcare costs in this population.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12887-024-05206-y.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Inflammatory bowel disease</kwd><kwd>Arthritis</kwd><kwd>Opioid</kwd><kwd>Healthcare utilization</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32-AR076951</award-id><award-id>K23-HL148539</award-id><award-id>K24-AR078950</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par5">Despite modern therapeutic advances, patients with inflammatory bowel disease (IBD), a disease that affects 1 in 1299 children in the United States [<xref ref-type="bibr" rid="CR1">1</xref>], often endure significant pain. The prevalence of abdominal pain, chronic non-abdominal pain, and arthralgia amongst children with IBD are 71%, 13%, and 41%, respectively [<xref ref-type="bibr" rid="CR2">2</xref>]. Arthritis and enthesitis are common extraintestinal manifestations of IBD, each affecting 20% of children with IBD [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Pain management in this patient population is challenging, as many effective analgesics have gastrointestinal (GI)-related adverse effects. Non-steroidal anti-inflammatory drugs (NSAIDs), salicylates, acetaminophen, and opioid analgesics are commonly used to alleviate pain. NSAIDs have a crucial role in the management of musculoskeletal pain in patients with other forms of inflammatory arthritis. However, many providers hesitate to use NSAIDs in children with IBD and arthritis or arthralgia due to their propensity to cause mucosal injury and evidence suggesting that they may precipitate IBD exacerbations [<xref ref-type="bibr" rid="CR5">5</xref>]. Guidelines from the American College of Gastroenterology strongly recommend avoiding NSAIDs when possible, in patients with Crohn&#8217;s disease, despite the low level of evidence suggesting an association of NSAIDs with IBD flares [<xref ref-type="bibr" rid="CR6">6</xref>]. Selective cyclooxygenase-<italic toggle="yes">2</italic> (Cox-2) inhibitors, a subclass of NSAIDs that have little to no Cox-1 affinity (the primary driver of IBD flare), may safely help to reduce articular pain and inflammation in IBD and serve as an opioid-sparing agent [<xref ref-type="bibr" rid="CR7">7</xref>]. Opioid use in patients with IBD has been linked to increased risks of serious infection and opioid use disorder [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. While the use of opioids among patients with IBD [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>] has become increasingly common, data about healthcare utilization for opioid use in this population remains sparse.</p><p id="Par6">Opioids are commonly used for acute pain management during a flare in IBD or after surgery. However, a substantial proportion of patients with IBD are also exposed to opioid analgesics for an extended period. 21&#8211;62% of adults with IBD are prescribed opioids at some point during outpatient or inpatient management [<xref ref-type="bibr" rid="CR12">12</xref>]. Additionally, this exposure is not limited to adults. One study showed that 9.3 to 12.2% of adolescents and young adults with IBD were chronically exposed to opioids between 2007 and 2015 [<xref ref-type="bibr" rid="CR10">10</xref>]. In another study, arthralgia and arthritis were significantly and independently associated with opioid use in children with IBD (OR: 1.9, 95% CI: 1.6&#8211;2.3 and OR:1.6, 95% CI: 1.2&#8211;2.2 respectively) [<xref ref-type="bibr" rid="CR2">2</xref>]. Additional factors significantly associated with opioid exposure included chronic non-abdominal pain, abdominal pain, chronic non-opioid analgesic use, substance use disorder, psychiatric comorbidities, and higher baseline disease severity indicators [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par7">Recent literature suggests that opioid exposure is a risk factor for increased healthcare spending in adults with IBD [<xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>]. Additionally, the cost of IBD care is largely driven by acute care utilization and medications [<xref ref-type="bibr" rid="CR12">12</xref>].Polypharmacy was found to be associated with opioid use in other patient populations [<xref ref-type="bibr" rid="CR16">16</xref>], but the impact of opioids on polypharmacy in IBD patients was not evaluated before. As the cost of managing IBD continues to rise [<xref ref-type="bibr" rid="CR17">17</xref>], identifying potential risk factors for high expenditure in the IBD population becomes more vital. In this study, we aimed to determine whether chronic opioid use was associated with higher acute care utilization in children with IBD and arthritis by leveraging a large, nationwide database that includes recipients of commercial insurance as well as Medicaid.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par8">The protocol for the conduct of this study was reviewed by the Children&#8217;s Hospital of Philadelphia Institutional Review Board and received a determination of non-human subject&#8217;s research.</p><sec id="Sec3"><title>Study design</title><p id="Par9">This was a retrospective cohort study of children less than 18 years of age with IBD and arthritis.</p></sec><sec id="Sec4"><title>Data source and data collection</title><p id="Par10">The data source was the Truven Health MarketScan Claims and Encounter Database from 2013 to 2019. This large nationwide database includes recipients of commercial insurance and Medicaid and comprises 33.5&#160;million unique individuals aged under 18 years. The database contains de-identified patient-level data, including medical diagnoses specified by the International Classification of Diseases, Ninth Revision (ICD)-9 and ICD-10 codes, financial variables (e.g., inpatient, outpatient, and pharmaceutical costs), and pharmacy-level data (e.g., National Drug Code, days&#8217; supply, strength, administration method).</p><p id="Par11">Patients with IBD were identified using a previously validated algorithm [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Patients must have fulfilled all of the following criteria: (1) Age&#8201;&lt;&#8201;18, (2) two or more distinct IBD diagnosis codes with a minimum separation date of 7 days (ICD-9 codes: 555.xx, 556.xx 558.9 [Chron&#8217;s disease, ulcerative colitis, unspecified or other noninfectious gastroenteritis or colitis respectively]; ICD-10 codes: K50.xx, K51.xx K52.3, K52.89, or K52.9 [Chron&#8217;s disease, ulcerative colitis, indeterminate colitis, other specified noninfective gastroenteritis and colitis, noninfective gastroenteritis and colitis, unspecified respectively]) [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]; (3) At least one of the codes must have been 555.xx, 556.xx, K50.xx, or K51.xx; (4) at least 1 year of continuous enrollment; and (5) at least 1 pharmacy claim. Within this group, patients with concomitant arthritis were identified by 1 of the following algorithms: 1)&#8201;&#8805;&#8201;2 codes indicating juvenile arthritis by any provider (ICD-10 codes: 713.1, 714.xx, 721.9, M08.xx, M45.x, L40.5 M07.xx.) on separate dates OR 2) at least one code indicating arthritis by any provider, <italic toggle="yes">plus</italic> at least one of the following: (a) medication code for intraarticular glucocorticoid(s) (triamcinolone, hydrocortisone, methylprednisolone, dexamethasone, and betamethasone), (b) procedure code indicating intraarticular injection (Current Procedural Terminology [CPT] codes 20600, 20605, 20610), or c)&#8201;&#8805;&#8201;1 code indicating JIA (Juvenile idiopathic arthritis) by a rheumatologist [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p></sec><sec id="Sec5"><title>Exposure and exposure density sampling</title><p id="Par12">Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref> illustrates the study design. The primary exposure was chronic opioid use in patients with IBD and arthritis, defined as &#8805;&#8201;3 prescription claims or &#8805;&#8201;90-day supply of opioids within one year [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Chronic opioid-exposed Patients and controls were matched on age-, sex-, and time since the first IBD claim at a 1 to 2 ratio using exposure density sampling. We matched for time from 1st IBD claim to minimize time-dependent bias [<xref ref-type="bibr" rid="CR23">23</xref>]. The index date for chronic opioid users was defined as the date of the first opioid prescription after participants met both IBD and the arthritis inclusion criteria. The following baseline covariates were assessed within the first 6 months after the index date: age, census region, sex, insurance type, biologic medication use, glucocorticoid use, chronic non-opioid analgesic use, selective cox-2 inhibitor use, and comorbidities (chronic non-abdominal pain disorders including migraine, unspecified chronic pain; psychiatric comorbidities including depression, anxiety, and substance use disorders.). Unspecified chronic pain diagnostic code is generally used when a patient&#8217;s pain cannot be explained by the activity of a known disease.</p><p id="Par13">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Study Design. Legend: Covariate assessment: Assessed within first 6 months after cohort entry. t<sub>0</sub>: index date t<sub>12</sub>: 12 months after index date t<sub>24</sub>: 24 months after index date. Exposed: Patients exposed to chronic opioid use</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e416" position="float" orientation="portrait" xlink:href="12887_2024_5206_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec6"><title>Outcome</title><p id="Par14">The primary outcome was acute healthcare utilization, defined as the total number of emergency department (ED) visits and hospitalizations within 12&#8211;24 months after the index date. Participants under 12 months of continuous enrollment after the index date were excluded. A secondary outcome was polypharmacy, categorized as minor (prescription of 2&#8211;4 medications of interest at a single encounter) or major (5 or more medications of interest at a single encounter) [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Medications assessed for polypharmacy included nonopioid analgesics, glucocorticoids, antidepressants, muscle relaxants, stimulants, anxiolytics, anticonvulsants, antipsychotics, opioid antagonists, prokinetic agents, antispasmodics, H1 and H2 receptor antagonists [<xref ref-type="bibr" rid="CR16">16</xref>]. Biologics and disease-modifying agents were not included in the definition of polypharmacy as these medication classes are necessary maintenance medications for the underlying condition(s).</p></sec><sec id="Sec7"><title>Analysis</title><p id="Par15">All statistical analyses were conducted with STATA version 16.1 (College Station, TX: StataCorp LLC). Demographics and clinical features were summarized using standard descriptive statistics. A negative binomial (NB) regression model was used to assess the association between acute care utilization and chronic opioid use due to the overdispersion of the outcome variable (median: 1, IQR: 0&#8211;3, supplementary Fig.&#160;<xref rid="MOESM1" ref-type="media">1</xref>). Person days were used as the offset to account for differential follow-up times. Baseline variables evaluated as potential confounders included public insurance, glucocorticoid exposure, biologic exposure, and diagnostic codes for psychiatric and chronic pain.</p><p id="Par16">Our primary outcome was over dispersed and included many zeros (39.5%). Therefore, sensitivity analyses were run using additional zero-inflated NB, zero-inflated Poisson, and Poisson regression models to compare the model performance to the NB regression model. Model fit was evaluated using the likelihood ratio test (LRT), Akaike information criterion (AIC), and the Bayesian information criterion (BIC). In the zero-inflated NB and Poisson models, follow-up time was used to estimate excess zeros, assuming that patients with shorter follow-ups are more likely to have &#8220;zero&#8221; hospital admissions and emergency visits.</p><p id="Par17">To assess the association between chronic opioid use and polypharmacy, a multivariable logistic regression model was built using a stepwise selection approach. The outcome was dichotomized as 0 for no polypharmacy and 1 for minor or major polypharmacy.</p></sec><sec id="Sec8" sec-type="results"><title>Results</title><p id="Par18">Of 14,943 meeting the definition for IBD, 480 (3.2%) met criteria for IBD and arthritis. 249/480 (52%) children with IBD and arthritis had at least one opioid claim. 59 (12%) met criteria for chronic opioid exposure, of which 46 had at least one year of follow-up and were included in the analysis, along with 98 matched controls without chronic opioid exposure. Participant demographics for the matched opioid-exposed and unexposed children with IBD and arthritis are summarized in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. The median age of the 144 patients analyzed was 15 years, and 32.6% were male. Among those who were chronically opioid exposed, the median number of days exposed in one year was 18 (IQR: 5, 64), and the median opioid prescription count in one year was 9 (IQR: 5, 16). 15 (33%) and 22 (22%) of the opioid-exposed and unexposed groups had pharmacy claims for a biologic medication. Glucocorticoid exposure and psychiatric comorbidities were significantly higher in those with chronic opioid exposure (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01 for both). Opioid-unexposed patients had a significantly longer duration of continuous enrollment after the index date (1199 vs. 638 days; <italic toggle="yes">p</italic>&#8201;=&#8201;0.02) and higher chronic non-opioid analgesic use compared to those who were opioid-exposed (49 vs. 2% <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01). Thirteen children in the exposed group and 20 children in the unexposed group were excluded due to having less than 12 months of follow-up time after the index date.</p><p id="Par19">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Demographic and baseline clinical features, distribution of Health Care utilization of pediatric IBD and arthritis patients with and without chronic opioid exposure</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Chronic opioid use<break/><italic toggle="yes">N</italic>&#8201;=&#8201;46</th><th align="left" colspan="1" rowspan="1">No chronic opioid use<break/><italic toggle="yes">N</italic>&#8201;=&#8201;98</th><th align="left" colspan="2" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1"/></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Median age [IQR]</td><td align="left" colspan="1" rowspan="1">15 (14,16)</td><td align="left" colspan="1" rowspan="1">15 (12,16)</td><td align="left" colspan="2" rowspan="1">0.16</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Male sex, n(%)</td><td align="left" colspan="1" rowspan="1">15(32.6)</td><td align="left" colspan="1" rowspan="1">32 (32.6)</td><td align="left" colspan="2" rowspan="1">1</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><p>Insurance payor</p><p>&#8195;Commercial</p><p>&#8195;Medicaid</p></td><td align="left" colspan="1" rowspan="1"><p>25 (54.3)</p><p>21 (45.6)</p></td><td align="left" colspan="1" rowspan="1"><p>58(59.1)</p><p>40 (40.8)</p></td><td align="left" colspan="2" rowspan="1">0.50</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Follow-up time, median days [IQR]</td><td align="left" colspan="1" rowspan="1">638 (635&#8211;1252)</td><td align="left" colspan="1" rowspan="1">1199 (707&#8211;1540)</td><td align="left" colspan="2" rowspan="1">0.02</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Biologic exposure</td><td align="left" colspan="1" rowspan="1">15 (32.6)</td><td align="left" colspan="1" rowspan="1">22 (22.4)</td><td align="left" colspan="2" rowspan="1">0.20</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Chronic non-opioid analgesic exposure</td><td align="left" colspan="1" rowspan="1">2 (4.3)</td><td align="left" colspan="1" rowspan="1">48 (48.9)</td><td align="left" colspan="2" rowspan="1">&lt;&#8201;0.01</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Glucocorticoid exposure</td><td align="left" colspan="1" rowspan="1">22 (47.8)</td><td align="left" colspan="1" rowspan="1">22 (22.4)</td><td align="left" colspan="2" rowspan="1">&lt;&#8201;0.01</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Cox-2 inhibitor exposure</td><td align="left" colspan="1" rowspan="1">6 (13.0)</td><td align="left" colspan="1" rowspan="1">12 (12.2)</td><td align="left" colspan="2" rowspan="1">0.80</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Chronic nonabdominal pain</td><td align="left" colspan="1" rowspan="1">23 (50.0)</td><td align="left" colspan="1" rowspan="1">36 (36.7)</td><td align="left" colspan="2" rowspan="1">0.10</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Psychiatric</td><td align="left" colspan="1" rowspan="1">28 (60.8)</td><td align="left" colspan="1" rowspan="1">37 (37.7)</td><td align="left" colspan="2" rowspan="1">&lt;&#8201;0.01</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Substance abuse disorder</td><td align="left" colspan="1" rowspan="1">4 (8.7)</td><td align="left" colspan="1" rowspan="1">5 (5.1)</td><td align="left" colspan="2" rowspan="1">0.40</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Number of outpatient visits, median</td><td align="left" colspan="1" rowspan="1">24.5 (10,44)</td><td align="left" colspan="2" rowspan="1">19.5 (11,28)</td><td align="left" colspan="2" rowspan="1">0.07</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8805;&#8201;1 ED visits, N (%)</td><td align="left" colspan="1" rowspan="1">30 (65.2)</td><td align="left" colspan="2" rowspan="1">50 (51.0)</td><td align="left" colspan="2" rowspan="1">0.10</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Hospitalizations, N (%)</p><p>&#8195;0</p><p>&#8195;1</p><p>&#8195;2</p><p>&#8195;3</p><p>&#8195;4</p><p>&#8195;&gt;5</p></td><td align="left" colspan="1" rowspan="1"><p>34 (73.9)</p><p>4 (8.7)</p><p>3 (6.5)</p><p>3 (6.5)</p><p>1 (2.1)</p><p>1 (2.1)</p></td><td align="left" colspan="2" rowspan="1"><p>85(86.7)</p><p>11(11.2)</p><p>1 (1)</p><p>1 (1)</p><p>0</p><p>0</p></td><td align="left" colspan="2" rowspan="1">0.03</td></tr><tr><td align="left" colspan="1" rowspan="1">Readmission ever*, N(%)</td><td align="left" colspan="1" rowspan="1">7 (15.2)</td><td align="left" colspan="2" rowspan="1">4 (4.1)</td><td align="left" colspan="2" rowspan="1">0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">Polypharmacy<sup>a</sup>, N(%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="2" rowspan="1"/><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">None</td><td align="left" colspan="1" rowspan="1">22 (47.8)</td><td align="left" colspan="2" rowspan="1">69 (70.4)</td><td align="left" colspan="2" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">Minor</td><td align="left" colspan="1" rowspan="1">21 (45.6)</td><td align="left" colspan="2" rowspan="1">29 (29.5)</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Major</td><td align="left" colspan="1" rowspan="1">3 (6.5)</td><td align="left" colspan="2" rowspan="1">0</td><td align="left" colspan="2" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>Legend: * Readmission to hospital within 30 days after discharge</p><p><sup>a</sup> Polypharmacy:</p><p>No polypharmacy&#8201;=&#8201;Less than 2 non-biologic medications of interest filled at a single encounter date</p><p>Minor polypharmacy&#8201;=&#8201;2 to 4 non-biologic medications of interest filled concurrently at a single encounter date</p><p>Major polypharmacy&#8201;=&#8201;5 or more non-biologic medications of interest filled at a single encounter date</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec9"><title>Acute healthcare use associated with chronic opioid exposure</title><p id="Par21">The frequency of outpatient and ED visits and hospitalization in chronic opioid-exposed and unexposed patients are listed in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. The proportion of patients who presented to the ED at least once was 65% for the chronic opioid-exposed group and 51% for the controls. Amongst those who were chronically opioid exposed, 26% had at least one hospitalization, and 17% were hospitalized more than once.</p><p id="Par22">Several clinical factors were independently and significantly associated with greater IRR of acute healthcare use in those with chronic opioid exposure versus matched controls (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Chronic opioid use had an increased incidence rate of hospitalizations and ED visits (IRR:1.7,95% CI:1.1&#8211;2.8; p-value: 0.02) compared to controls. Additionally, public insurance (IRR: 2.2, 95% CI: 1.4&#8211;3.5) and having a chronic pain condition (IRR: 2.2, 95% CI: 1.4&#8211;3.4) were independently and significantly associated with a higher IRR of acute health care use. Glucocorticoid use, biologic use, and comorbid psychiatric conditions during the baseline period were not significantly associated with higher acute health care use in children with IBD and arthritis.</p><p id="Par23">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Association between chronic opioid use and acute health care use adjusting for covariates</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Baseline factors</th><th align="left" colspan="2" rowspan="1">Univariable Regression</th><th align="left" colspan="2" rowspan="1">Multivariable Regression<break/><italic toggle="yes">N</italic>&#8201;=&#8201;144</th></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">IRR (95% CI)</th><th align="left" colspan="1" rowspan="1">p-value</th><th align="left" colspan="1" rowspan="1">IRR (95% CI)</th><th align="left" colspan="1" rowspan="1">p-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Chronic opioid use</td><td align="left" colspan="1" rowspan="1">1.6 (1.0-2.6)</td><td align="left" colspan="1" rowspan="1">0.04</td><td align="left" colspan="1" rowspan="1">1.7 (1.1&#8211;2.8)</td><td align="left" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">Public insurance</td><td align="left" colspan="1" rowspan="1">1.6 (1.0-2.5)</td><td align="left" colspan="1" rowspan="1">0.03</td><td align="left" colspan="1" rowspan="1">2.2 (1.4&#8211;3.5)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">Glucocorticoid exposure</td><td align="left" colspan="1" rowspan="1">0.9 (0.6&#8211;1.5)</td><td align="left" colspan="1" rowspan="1">0.76</td><td align="left" colspan="1" rowspan="1">0.7 (0.4&#8211;1.1)</td><td align="left" colspan="1" rowspan="1">0.1</td></tr><tr><td align="left" colspan="1" rowspan="1">Chronic non-opioid analgesic use</td><td align="left" colspan="1" rowspan="1">1.3 (0.8-2.0)</td><td align="left" colspan="1" rowspan="1">0.33</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Cox-2 inhibitor exposure</td><td align="left" colspan="1" rowspan="1">1.94 (1.0-3.7)</td><td align="left" colspan="1" rowspan="1">0.04</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Biologic exposure</td><td align="left" colspan="1" rowspan="1">1.1 (0.7&#8211;1.9)</td><td align="left" colspan="1" rowspan="1">0.60</td><td align="left" colspan="1" rowspan="1">1.2 (0.7&#8211;1.9)</td><td align="left" colspan="1" rowspan="1">0.5</td></tr><tr><td align="left" colspan="1" rowspan="1">Psychiatric diagnosis</td><td align="left" colspan="1" rowspan="1">1.2 (0.8&#8211;1.9)</td><td align="left" colspan="1" rowspan="1">0.32</td><td align="left" colspan="1" rowspan="1">1.2 (0.8&#8211;1.9)</td><td align="left" colspan="1" rowspan="1">0.4</td></tr><tr><td align="left" colspan="1" rowspan="1">Chronic pain conditions</td><td align="left" colspan="1" rowspan="1">1.8 (1.2&#8211;2.8)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.01</td><td align="left" colspan="1" rowspan="1">2.2 (1.4&#8211;3.4)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">Substance abuse disorder</td><td align="left" colspan="1" rowspan="1">1.7 (0.7&#8211;4.2)</td><td align="left" colspan="1" rowspan="1">0.21</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>Legend: Results of negative binomial regression models</p><p>Health care use is a composite outcome&#8201;=&#8201;Number of ED visits&#8201;+&#8201;Hospitalizations within 12&#8211;24 months after the index date</p></table-wrap-foot></table-wrap>
</p><p id="Par24">Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref> demonstrates the sensitivity analysis results of different regression models. Zero-inflated NB and standard NB had comparable performance, as evidenced by similar AIC and BIC and a non-significant p-value of LRT. This suggests that adding the zero-inflated term did not significantly improve the model&#8217;s performance, supporting the selection of the standard NB regression model.</p></sec><sec id="Sec10"><title>Association between chronic opioid use and polypharmacy</title><p id="Par25">Polypharmacy was observed in 24 (52%) and 29 (30%) opioid-exposed and unexposed patients, respectively. Results of the univariate and multivariable logistic regression models to evaluate the association of chronic opioid use and other baseline covariates with polypharmacy are shown in Table&#160;<xref rid="Tab3" ref-type="table">3</xref>. Chronic opioid exposure was significantly associated with polypharmacy in the univariate but not the multivariable model. However, biologic exposure (OR: 2.7, 95% CI: 1.2&#8211;6.3) and chronic pain (OR: 3.6, 95% CI: 1.7&#8211;7.7) were independently and statistically associated with higher odds of polypharmacy.</p><p id="Par26">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Association between chronic opioid use and presence of polypharmacy adjusting for covariates</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Baseline factors</th><th align="left" colspan="2" rowspan="1">Univariable Regression</th><th align="left" colspan="2" rowspan="1">Multivariable Regression</th></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">OR (95% CI)</th><th align="left" colspan="1" rowspan="1">p-value</th><th align="left" colspan="1" rowspan="1">OR (95% CI)</th><th align="left" colspan="1" rowspan="1">p-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Chronic opioid use</td><td align="left" colspan="1" rowspan="1">2.6 (1.2&#8211;5.3)</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">1.96 (0.9&#8211;4.3)</td><td align="left" colspan="1" rowspan="1">0.09</td></tr><tr><td align="left" colspan="1" rowspan="1">Public insurance</td><td align="left" colspan="1" rowspan="1">1.5 (0.7-3.0)</td><td align="left" colspan="1" rowspan="1">0.21</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Glucocorticoid exposure</td><td align="left" colspan="1" rowspan="1">1.9 (0.9-4.0)</td><td align="left" colspan="1" rowspan="1">0.07</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Chronic non-opioid analgesic use</td><td align="left" colspan="1" rowspan="1">0.7 (0.4&#8211;1.5)</td><td align="left" colspan="1" rowspan="1">0.38</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Cox-2 inhibitor exposure</td><td align="left" colspan="1" rowspan="1">2.4 (0.9&#8211;6.5)</td><td align="left" colspan="1" rowspan="1">0.08</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Biologic exposure</td><td align="left" colspan="1" rowspan="1">2.6 (1.2&#8211;5.6)</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">2.7 (1.2&#8211;6.3)</td><td align="left" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">Psychiatric</td><td align="left" colspan="1" rowspan="1">2.3 (1.2&#8211;4.7)</td><td align="left" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">1.9 (0.9&#8211;4.1)</td><td align="left" colspan="1" rowspan="1">0.09</td></tr><tr><td align="left" colspan="1" rowspan="1">Chronic pain conditions</td><td align="left" colspan="1" rowspan="1">3.6 (1.8&#8211;7.3)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.01</td><td align="left" colspan="1" rowspan="1">3.6 (1.7&#8211;7.7)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">Substance abuse disorder</td><td align="left" colspan="1" rowspan="1">0.8 (0.2&#8211;3.5)</td><td align="left" colspan="1" rowspan="1">0.82</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>Legend: Results of logistic regression model</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec11" sec-type="discussion"><title>Discussion</title><p id="Par28">This study evaluated the magnitude of the impact of chronic opioid use on acute care utilization in a subset of IBD patients with comorbid arthritis. Chronic opioid use was significantly associated with greater IRR of acute health care utilization, even after adjusting for other covariates. Furthermore, we identified several other patient characteristics significantly associated with higher acute healthcare utilization, including public insurance and the presence of a chronic pain condition. The prevalence of polypharmacy in our cohort was 36%.</p><p id="Par29">Arthritis is one of the most common causes of pain in IBD patients and was significantly associated with chronic opioid use in several studies [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. In this population-based study, the rate of chronic opioid use among children with IBD and arthritis within 12 months of the index date was 12.3%. This result is compatible with a previous study reporting 10.6% chronic opioid users among adults with IBD [<xref ref-type="bibr" rid="CR27">27</xref>] and another study reporting annual prevalence of opioid use among rheumatoid arthritis patients as 16.9% [<xref ref-type="bibr" rid="CR28">28</xref>]. Opioid use and acute care utilization are associated with increased healthcare spending in adults with IBD [<xref ref-type="bibr" rid="CR29">29</xref>]. Given the increasing costs of IBD care, identifying opportunities to potentially decrease healthcare utilization and costs is critical. There are only a few randomized controlled trials investigating the safety of selective cox-2 inhibitors in IBD patients, and they did not find any association between the use of these medications and IBD flares [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. However, the overall quality of evidence supporting this outcome was low due to small sample sizes and low event counts [<xref ref-type="bibr" rid="CR32">32</xref>]. Future studies with larger sample sizes are needed to conclude that selective cox-2 inhibitors are a safe alternative to opioids in pain management in IBD patients. Aside from selective cox-2 inhibitors, non-pharmacological pain management options such as physical therapy can be considered for management of joint pain in patients with IBD and arthritis.</p><p id="Par30">Patients might be prescribed opioids after surgeries, however post-surgical opioid use is expected to be utilized in the short term. Since our primary exposure was chronic opioid use, we did not exclude patients with history of surgery.</p><p id="Par31">Our data builds upon data demonstrating the negative impact of opioid use in IBD patients. Opioid use in adults with IBD is associated with increased hospitalizations, healthcare costs, ED visits, outpatient visits, and polypharmacy [<xref ref-type="bibr" rid="CR12">12</xref>]. Importantly, we did not include outpatient visits in our primary outcome as higher counts of outpatient visits in opioid-exposed patients may be attributable to controlled substance monitoring and not adverse effects of exposure. Furthermore, increased outpatient visits could provide the opportunity for better symptom monitoring, which may lead to improved patient outcomes. However, ED visits and hospitalizations are unlikely to be attributable to monitoring and are more likely to be attributable to unplanned acute care.</p><p id="Par32">Opioids may contribute to increased healthcare use through several potential mechanisms. Opioids may directly increase the severity of underlying IBD activity, leading to more frequent acute healthcare needs. There is preliminary evidence which suggests that opioid use may trigger IBD activity by impairing intestinal wound healing (via the alteration of opioid-signaling pathways) [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>], and by augmenting the gut inflammatory response (via the regulation of neuropeptides, such as substance P) [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. We attempted to address IBD disease activity as a confounder in our analysis by matching cases and control on time since the 1st IBD diagnosis code and including glucocorticoid use and biologic therapy within the first six months after the index date as proxies for disease severity. However, there is likely some residual confounding that we cannot measure, given the administrative nature of the data. Patients using opioids for an extended time could also develop narcotic bowel syndrome, which could lead to increased acute care visits and healthcare costs; this condition is characterized by incompletely controlled, recurrent abdominal pain despite continued or increasing doses of opioids thought to be centrally mediated (Aka opioid hyperalgesia) [<xref ref-type="bibr" rid="CR37">37</xref>]. Similarly, opioid-induced hyperalgesia was reported in a patient with juvenile idiopathic arthritis [<xref ref-type="bibr" rid="CR38">38</xref>]. Several previous studies showed that anxiety and depression increase health care utilization in IBD patients [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Therefore we accounted for this factor as a confounder. In our cohort these comorbidities were not found independently associated with increased healthcare utilization which might be related to better access to mental health care services for a subset of individuals in the database. or lack of identification of anxiety and depression due to inadequate screening of patients in the database.</p><p id="Par33">Polypharmacy has been previously described in IBD patients [<xref ref-type="bibr" rid="CR41">41</xref>]. Several studies report that chronic opioid use in patients with IBD is associated with polypharmacy [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. This association did not reach statistical significance in our multivariate logistic regression. It is possible that we were unable to detect the true effect of chronic opioid use on polypharmacy due to the small sample size since the effect estimate was quite high (OR: 1.96).</p><p id="Par34">This study had several limitations, including those inherent to using administrative claims data, including misclassification bias, missing data, and confounding by indication. Inaccuracies in ICD &#8722;&#8201;9/10 code documentation could cause misclassification bias. However, we anticipate minimal misclassification in diagnosis since we used validated case definition criteria for both IBD and arthritis [<xref ref-type="bibr" rid="CR18">18</xref>&#8211;<xref ref-type="bibr" rid="CR21">21</xref>]. There was no missing data on primary exposure, key variables, and outcomes. Race data was unavailable in the dataset for commercially insured patients, and geographic region data was unavailable for Medicaid beneficiaries. Therefore, we could not evaluate the impact of these variables on healthcare utilization, which might be a potential confounder. Children without chronic opioid exposure had significantly longer follow-up times after the index date. This differential loss to follow-up, if anything, would underestimate the impact of chronic opioid exposure on healthcare utilization, biasing our findings toward the null. However, we used person-days of follow-up as an offset to account for differential follow-up times. Certain patient-level factors could be associated with both chronic opioid use and acute health care utilization, such as disease severity and comorbidities, which could cause confounding by indication. We built a parsimonious multivariable regression model to try and account for these factors. We used a composite outcome consisting of several ED visits and hospitalizations because of the relatively low event rate and limited power to demonstrate the effect of chronic opioid exposure on individual outcomes. Each component of the composite outcome is given the same importance, although the cost associated with each of these components may be very different. A formal cost analysis was beyond the scope of this study. Future studies can be planned to evaluate the effect of chronic opioid use on healthcare costs associated with ED visits, outpatient visits, and hospitalizations in children with IBD and arthritis.</p></sec><sec id="Sec12" sec-type="conclusion"><title>Conclusions</title><p id="Par35">Our results indicate that opioid use in children with IBD and arthritis was associated with significantly higher acute healthcare utilization. With the ongoing opioid epidemic and rising healthcare costs, pediatric providers should continue to make efforts to reduce opioid use in this population. There is a vital need to identify non-opioid alternatives for pain management in patients with IBD and concomitant arthritis.</p></sec><sec id="Sec13" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12887_2024_5206_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>ABD designed the study, performed statistical analysis, and was a major contributor in writing the manuscript. SJ performed the sensitivity analysis comparing different regression models. JC assisted in study design and was a major contributor in writing and editing the manuscript. AG assisted in building case definition algorithm. RX assisted in study design and statistical analysis. PW assisted in study design and was a major contributor in writing and editing the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>ABD was supported by the National Institutes of Health (NIH) T32 (AR076951-01) and K24 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AR078950">AR078950</ext-link>, awarded to PW). J.C. was supported by NIH K23-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="HL148539">HL148539</ext-link>.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par36">The Children&#8217;s Hospital of Philadelphia (CHOP) Institutional Review Board (IRB) reviewed this study and granted a waiver of consent.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par37">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par38">The authors declare no competing interests.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>IBD</term><def><p id="Par39">Inflammatory bowel disease</p></def></def-item><def-item><term>GI</term><def><p id="Par40">Gastrointestinal</p></def></def-item><def-item><term>NSAIDs</term><def><p id="Par41">Non-steroidal anti-inflammatory drugs</p></def></def-item><def-item><term>Cox-2</term><def><p id="Par42">cyclooxygenase-2</p></def></def-item><def-item><term>OR</term><def><p id="Par43">Odds ratio</p></def></def-item><def-item><term>ICD</term><def><p id="Par44">International Classification of Diseases</p></def></def-item><def-item><term>ED</term><def><p id="Par45">Emergency department</p></def></def-item><def-item><term>NB</term><def><p id="Par46">Negative binominal</p></def></def-item><def-item><term>LRT</term><def><p id="Par47">Likelihood ratio test</p></def></def-item><def-item><term>AIC</term><def><p id="Par48">Akaike information criterion</p></def></def-item><def-item><term>BIC</term><def><p id="Par49">Bayesian information criterion</p></def></def-item><def-item><term>IQR</term><def><p id="Par50">Interquartile range</p></def></def-item><def-item><term>IRR</term><def><p id="Par51">Incidence rate ratio</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>Y</given-names></name><name name-style="western"><surname>Manne</surname><given-names>S</given-names></name><name name-style="western"><surname>Treem</surname><given-names>WR</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D</given-names></name></person-group><article-title>Prevalence of inflammatory Bowel Disease in Pediatric and adult populations: recent estimates from large National databases in the United States, 2007&#8211;2016</article-title><source>Inflamm Bowel Dis</source><year>2020</year><volume>26</volume><issue>4</issue><fpage>619</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">31504515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ibd/izz182</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Ye Y, Manne S, Treem WR, Bennett D. Prevalence of inflammatory Bowel Disease in Pediatric and adult populations: recent estimates from large National databases in the United States, 2007&#8211;2016. Inflamm Bowel Dis. 2020;26(4):619&#8211;25.<pub-id pub-id-type="pmid">31504515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ibd/izz182</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Bilgic Dagci AO, Chang JC, Xiao R, Grossman AB, Weiss PF. Opioid use in children with inflammatory bowel disease-related arthritis. Clin Exp Rheumatol. 2023.<pub-id pub-id-type="doi" assigning-authority="pmc">10.55563/clinexprheumatol/3bu1sf</pub-id><pub-id pub-id-type="pmcid">PMC10523932</pub-id><pub-id pub-id-type="pmid">37083174</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bilgic Dagci</surname><given-names>AO</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JC</given-names></name><name name-style="western"><surname>Brandon</surname><given-names>TG</given-names></name><name name-style="western"><surname>Goheer</surname><given-names>HE</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>PF</given-names></name></person-group><article-title>Clinical features, treatment patterns and short-term outcomes of children with inflammatory bowel disease evaluated in rheumatology clinic</article-title><source>Clin Exp Rheumatol</source><year>2022</year><volume>40</volume><issue>5</issue><fpage>1045</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">35349409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.55563/clinexprheumatol/2xhxrk</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Bilgic Dagci AO, Chang JC, Brandon TG, Goheer HE, Weiss PF. Clinical features, treatment patterns and short-term outcomes of children with inflammatory bowel disease evaluated in rheumatology clinic. Clin Exp Rheumatol. 2022;40(5):1045&#8211;51.<pub-id pub-id-type="pmid">35349409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.55563/clinexprheumatol/2xhxrk</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Horton DB, Sherry DD, Baldassano RN, Weiss PF. Enthesitis is an Extraintestinal Manifestation of Pediatric Inflammatory Bowel Disease. Ann Paediatr Rheumatol. 2012;1(4).<pub-id pub-id-type="doi" assigning-authority="pmc">10.5455/apr.102920121510</pub-id><pub-id pub-id-type="pmcid">PMC3860180</pub-id><pub-id pub-id-type="pmid">24349861</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niccum</surname><given-names>B</given-names></name><name name-style="western"><surname>Moninuola</surname><given-names>O</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K</given-names></name><name name-style="western"><surname>Khalili</surname><given-names>H</given-names></name></person-group><article-title>Opioid use among patients with inflammatory bowel disease: a systematic review and Meta-analysis</article-title><source>Clin Gastroenterol Hepatol</source><year>2021</year><volume>19</volume><issue>5</issue><fpage>895</fpage><lpage>e9074</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2020.08.041</pub-id><pub-id pub-id-type="pmid">32835841</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Niccum B, Moninuola O, Miller K, Khalili H. Opioid use among patients with inflammatory bowel disease: a systematic review and Meta-analysis. Clin Gastroenterol Hepatol. 2021;19(5):895&#8211;e9074.<pub-id pub-id-type="pmid">32835841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2020.08.041</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lichtenstein</surname><given-names>GR</given-names></name><name name-style="western"><surname>Loftus</surname><given-names>EV</given-names></name><name name-style="western"><surname>Isaacs</surname><given-names>KL</given-names></name><name name-style="western"><surname>Regueiro</surname><given-names>MD</given-names></name><name name-style="western"><surname>Gerson</surname><given-names>LB</given-names></name><name name-style="western"><surname>Sands</surname><given-names>BE</given-names></name></person-group><article-title>ACG Clinical Guideline: management of Crohn&#8217;s disease in adults</article-title><source>Am J Gastroenterol</source><year>2018</year><volume>113</volume><issue>4</issue><fpage>481</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/ajg.2018.27</pub-id><pub-id pub-id-type="pmid">29610508</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: management of Crohn&#8217;s disease in adults. Am J Gastroenterol. 2018;113(4):481&#8211;517.<pub-id pub-id-type="pmid">29610508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ajg.2018.27</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribaldone</surname><given-names>DG</given-names></name><name name-style="western"><surname>Fagoonee</surname><given-names>S</given-names></name><name name-style="western"><surname>Astegiano</surname><given-names>M</given-names></name><name name-style="western"><surname>De Angelis</surname><given-names>C</given-names></name><name name-style="western"><surname>Smedile</surname><given-names>A</given-names></name><name name-style="western"><surname>Caviglia</surname><given-names>GP</given-names></name><etal/></person-group><article-title>Coxib&#8217;s safety in patients with inflammatory Bowel diseases: a Meta-analysis</article-title><source>Pain Physician</source><year>2015</year><volume>18</volume><issue>6</issue><fpage>599</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.36076/ppj.2015/18/599</pub-id><pub-id pub-id-type="pmid">26606012</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Ribaldone DG, Fagoonee S, Astegiano M, De Angelis C, Smedile A, Caviglia GP, et al. Coxib&#8217;s safety in patients with inflammatory Bowel diseases: a Meta-analysis. Pain Physician. 2015;18(6):599&#8211;607.<pub-id pub-id-type="pmid">26606012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lichtenstein</surname><given-names>GR</given-names></name><name name-style="western"><surname>Feagan</surname><given-names>BG</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>RD</given-names></name><name name-style="western"><surname>Salzberg</surname><given-names>BA</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>RH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Serious infections and mortality in association with therapies for Crohn&#8217;s disease: TREAT registry</article-title><source>Clin Gastroenterol Hepatol</source><year>2006</year><volume>4</volume><issue>5</issue><fpage>621</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2006.03.002</pub-id><pub-id pub-id-type="pmid">16678077</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn&#8217;s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4(5):621&#8211;30.<pub-id pub-id-type="pmid">16678077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2006.03.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen-Mekelburg</surname><given-names>S</given-names></name><name name-style="western"><surname>Rosenblatt</surname><given-names>R</given-names></name><name name-style="western"><surname>Gold</surname><given-names>S</given-names></name><name name-style="western"><surname>Burakoff</surname><given-names>R</given-names></name><name name-style="western"><surname>Waljee</surname><given-names>AK</given-names></name><name name-style="western"><surname>Saini</surname><given-names>S</given-names></name><etal/></person-group><article-title>The impact of opioid epidemic Trends on Hospitalised Inflammatory Bowel Disease patients</article-title><source>J Crohns Colitis</source><year>2018</year><volume>12</volume><issue>9</issue><fpage>1030</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">29741667</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ecco-jcc/jjy062</pub-id><pub-id pub-id-type="pmcid">PMC6113704</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Cohen-Mekelburg S, Rosenblatt R, Gold S, Burakoff R, Waljee AK, Saini S, et al. The impact of opioid epidemic Trends on Hospitalised Inflammatory Bowel Disease patients. J Crohns Colitis. 2018;12(9):1030&#8211;5.<pub-id pub-id-type="pmid">29741667</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ecco-jcc/jjy062</pub-id><pub-id pub-id-type="pmcid">PMC6113704</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wren</surname><given-names>AA</given-names></name><name name-style="western"><surname>Bensen</surname><given-names>R</given-names></name><name name-style="western"><surname>Sceats</surname><given-names>L</given-names></name><name name-style="western"><surname>Dehghan</surname><given-names>M</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name><name name-style="western"><surname>Wong</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Starting Young: Trends in Opioid Therapy among US adolescents and young adults with inflammatory bowel disease in the Truven MarketScan Database between 2007 and 2015</article-title><source>Inflamm Bowel Dis</source><year>2018</year><volume>24</volume><issue>10</issue><fpage>2093</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1093/ibd/izy222</pub-id><pub-id pub-id-type="pmid">29986015</pub-id><pub-id pub-id-type="pmcid">PMC6692855</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Wren AA, Bensen R, Sceats L, Dehghan M, Yu H, Wong JJ, et al. Starting Young: Trends in Opioid Therapy among US adolescents and young adults with inflammatory bowel disease in the Truven MarketScan Database between 2007 and 2015. Inflamm Bowel Dis. 2018;24(10):2093&#8211;103.<pub-id pub-id-type="pmid">29986015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ibd/izy222</pub-id><pub-id pub-id-type="pmcid">PMC6692855</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burr</surname><given-names>NE</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C</given-names></name><name name-style="western"><surname>West</surname><given-names>R</given-names></name><name name-style="western"><surname>Hull</surname><given-names>MA</given-names></name><name name-style="western"><surname>Subramanian</surname><given-names>V</given-names></name></person-group><article-title>Increasing prescription of opiates and mortality in patients with inflammatory bowel diseases in England</article-title><source>Clin Gastroenterol Hepatol</source><year>2018</year><volume>16</volume><issue>4</issue><fpage>534</fpage><lpage>e416</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2017.10.022</pub-id><pub-id pub-id-type="pmid">29079223</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Burr NE, Smith C, West R, Hull MA, Subramanian V. Increasing prescription of opiates and mortality in patients with inflammatory bowel diseases in England. Clin Gastroenterol Hepatol. 2018;16(4):534&#8211;e416.<pub-id pub-id-type="pmid">29079223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2017.10.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheehan</surname><given-names>JL</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>J</given-names></name><name name-style="western"><surname>Berinstein</surname><given-names>EM</given-names></name><name name-style="western"><surname>Greene-Higgs</surname><given-names>L</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>CA</given-names></name><name name-style="western"><surname>Berry</surname><given-names>SK</given-names></name><etal/></person-group><article-title>The Relationship between Opioid Use and Healthcare utilization in patients with inflammatory bowel disease: a systematic review and Meta-analysis</article-title><source>Inflamm Bowel Dis</source><year>2022</year><volume>28</volume><issue>12</issue><fpage>1904</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1093/ibd/izac021</pub-id><pub-id pub-id-type="pmid">35230420</pub-id><pub-id pub-id-type="pmcid">PMC9924039</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Sheehan JL, Jacob J, Berinstein EM, Greene-Higgs L, Steiner CA, Berry SK, et al. The Relationship between Opioid Use and Healthcare utilization in patients with inflammatory bowel disease: a systematic review and Meta-analysis. Inflamm Bowel Dis. 2022;28(12):1904&#8211;14.<pub-id pub-id-type="pmid">35230420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ibd/izac021</pub-id><pub-id pub-id-type="pmcid">PMC9924039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Limsrivilai</surname><given-names>J</given-names></name><name name-style="western"><surname>Stidham</surname><given-names>RW</given-names></name><name name-style="western"><surname>Govani</surname><given-names>SM</given-names></name><name name-style="western"><surname>Waljee</surname><given-names>AK</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>PD</given-names></name></person-group><article-title>Factors that Predict High Health Care utilization and costs for patients with inflammatory Bowel diseases</article-title><source>Clin Gastroenterol Hepatol</source><year>2017</year><volume>15</volume><issue>3</issue><fpage>385</fpage><lpage>e922</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2016.09.012</pub-id><pub-id pub-id-type="pmid">27645518</pub-id><pub-id pub-id-type="pmcid">PMC5503504</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Limsrivilai J, Stidham RW, Govani SM, Waljee AK, Huang W, Higgins PD. Factors that Predict High Health Care utilization and costs for patients with inflammatory Bowel diseases. Clin Gastroenterol Hepatol. 2017;15(3):385&#8211;e922.<pub-id pub-id-type="pmid">27645518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2016.09.012</pub-id><pub-id pub-id-type="pmcid">PMC5503504</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Click</surname><given-names>B</given-names></name><name name-style="western"><surname>Ramos Rivers</surname><given-names>C</given-names></name><name name-style="western"><surname>Koutroubakis</surname><given-names>IE</given-names></name><name name-style="western"><surname>Babichenko</surname><given-names>D</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>AM</given-names></name><name name-style="western"><surname>Hashash</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Demographic and clinical predictors of High Healthcare Use in patients with inflammatory bowel disease</article-title><source>Inflamm Bowel Dis</source><year>2016</year><volume>22</volume><issue>6</issue><fpage>1442</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/MIB.0000000000000763</pub-id><pub-id pub-id-type="pmid">26950309</pub-id><pub-id pub-id-type="pmcid">PMC4868776</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Click B, Ramos Rivers C, Koutroubakis IE, Babichenko D, Anderson AM, Hashash JG, et al. Demographic and clinical predictors of High Healthcare Use in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(6):1442&#8211;9.<pub-id pub-id-type="pmid">26950309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MIB.0000000000000763</pub-id><pub-id pub-id-type="pmcid">PMC4868776</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>BB</given-names></name><name name-style="western"><surname>Click</surname><given-names>BH</given-names></name><name name-style="western"><surname>Koutroubakis</surname><given-names>IE</given-names></name><name name-style="western"><surname>Ramos Rivers</surname><given-names>C</given-names></name><name name-style="western"><surname>Regueiro</surname><given-names>M</given-names></name><name name-style="western"><surname>Swoger</surname><given-names>J</given-names></name><etal/></person-group><article-title>The cost of Crohn&#8217;s Disease: Varied Health Care expenditure patterns across distinct Disease trajectories</article-title><source>Inflamm Bowel Dis</source><year>2017</year><volume>23</volume><issue>1</issue><fpage>107</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1097/MIB.0000000000000977</pub-id><pub-id pub-id-type="pmid">27930405</pub-id><pub-id pub-id-type="pmcid">PMC5177495</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Rao BB, Click BH, Koutroubakis IE, Ramos Rivers C, Regueiro M, Swoger J, et al. The cost of Crohn&#8217;s Disease: Varied Health Care expenditure patterns across distinct Disease trajectories. Inflamm Bowel Dis. 2017;23(1):107&#8211;15.<pub-id pub-id-type="pmid">27930405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MIB.0000000000000977</pub-id><pub-id pub-id-type="pmcid">PMC5177495</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gmuca</surname><given-names>S</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>R</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>PF</given-names></name><name name-style="western"><surname>Sherry</surname><given-names>DD</given-names></name><name name-style="western"><surname>Knight</surname><given-names>AM</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>JS</given-names></name></person-group><article-title>Opioid prescribing and polypharmacy in children with Chronic Musculoskeletal Pain</article-title><source>Pain Med</source><year>2019</year><volume>20</volume><issue>3</issue><fpage>495</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1093/pm/pny116</pub-id><pub-id pub-id-type="pmid">29905842</pub-id><pub-id pub-id-type="pmcid">PMC6387982</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Gmuca S, Xiao R, Weiss PF, Sherry DD, Knight AM, Gerber JS. Opioid prescribing and polypharmacy in children with Chronic Musculoskeletal Pain. Pain Med. 2019;20(3):495&#8211;503.<pub-id pub-id-type="pmid">29905842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/pm/pny116</pub-id><pub-id pub-id-type="pmcid">PMC6387982</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Qian</surname><given-names>AS</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>NH</given-names></name><name name-style="western"><surname>Ho</surname><given-names>SKM</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J</given-names></name><name name-style="western"><surname>Jairath</surname><given-names>V</given-names></name><etal/></person-group><article-title>Trends in U.S. Health Care spending on inflammatory Bowel diseases, 1996&#8211;2016</article-title><source>Inflamm Bowel Dis</source><year>2022</year><volume>28</volume><issue>3</issue><fpage>364</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1093/ibd/izab074</pub-id><pub-id pub-id-type="pmid">33988697</pub-id><pub-id pub-id-type="pmcid">PMC8889287</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Singh S, Qian AS, Nguyen NH, Ho SKM, Luo J, Jairath V, et al. Trends in U.S. Health Care spending on inflammatory Bowel diseases, 1996&#8211;2016. Inflamm Bowel Dis. 2022;28(3):364&#8211;72.<pub-id pub-id-type="pmid">33988697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ibd/izab074</pub-id><pub-id pub-id-type="pmcid">PMC8889287</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Allison</surname><given-names>JE</given-names></name><name name-style="western"><surname>Herrinton</surname><given-names>LJ</given-names></name></person-group><article-title>Validity of computerized diagnoses, procedures, and drugs for inflammatory bowel disease in a northern California managed care organization</article-title><source>Pharmacoepidemiol Drug Saf</source><year>2009</year><volume>18</volume><issue>11</issue><fpage>1086</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1002/pds.1824</pub-id><pub-id pub-id-type="pmid">19672855</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Liu L, Allison JE, Herrinton LJ. Validity of computerized diagnoses, procedures, and drugs for inflammatory bowel disease in a northern California managed care organization. Pharmacoepidemiol Drug Saf. 2009;18(11):1086&#8211;93.<pub-id pub-id-type="pmid">19672855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pds.1824</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buckley</surname><given-names>LH</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>R</given-names></name><name name-style="western"><surname>Perman</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Grossman</surname><given-names>AB</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>PF</given-names></name></person-group><article-title>Psoriasis Associated with Tumor necrosis factor inhibitors in Children with Inflammatory diseases</article-title><source>Arthritis Care Res (Hoboken)</source><year>2021</year><volume>73</volume><issue>2</issue><fpage>215</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1002/acr.24100</pub-id><pub-id pub-id-type="pmid">31646743</pub-id><pub-id pub-id-type="pmcid">PMC8176628</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Buckley LH, Xiao R, Perman MJ, Grossman AB, Weiss PF. Psoriasis Associated with Tumor necrosis factor inhibitors in Children with Inflammatory diseases. Arthritis Care Res (Hoboken). 2021;73(2):215&#8211;20.<pub-id pub-id-type="pmid">31646743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acr.24100</pub-id><pub-id pub-id-type="pmcid">PMC8176628</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beukelman</surname><given-names>T</given-names></name><name name-style="western"><surname>Xie</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Baddley</surname><given-names>JW</given-names></name><name name-style="western"><surname>Delzell</surname><given-names>E</given-names></name><name name-style="western"><surname>Grijalva</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment</article-title><source>Arthritis Rheum</source><year>2012</year><volume>64</volume><issue>8</issue><fpage>2773</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1002/art.34458</pub-id><pub-id pub-id-type="pmid">22569881</pub-id><pub-id pub-id-type="pmcid">PMC3409300</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64(8):2773&#8211;80.<pub-id pub-id-type="pmid">22569881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.34458</pub-id><pub-id pub-id-type="pmcid">PMC3409300</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brandon</surname><given-names>TG</given-names></name><name name-style="western"><surname>Manos</surname><given-names>CK</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>R</given-names></name><name name-style="western"><surname>Ogdie</surname><given-names>A</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>PF</given-names></name></person-group><article-title>Pediatric psoriatic arthritis: a population-based cohort study of risk factors for onset and subsequent risk of inflammatory comorbidities</article-title><source>J Psoriasis Psoriatic Arthritis</source><year>2018</year><volume>3</volume><issue>4</issue><fpage>131</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1177/2475530318799072</pub-id><pub-id pub-id-type="pmid">31355354</pub-id><pub-id pub-id-type="pmcid">PMC6660180</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Brandon TG, Manos CK, Xiao R, Ogdie A, Weiss PF. Pediatric psoriatic arthritis: a population-based cohort study of risk factors for onset and subsequent risk of inflammatory comorbidities. J Psoriasis Psoriatic Arthritis. 2018;3(4):131&#8211;6.<pub-id pub-id-type="pmid">31355354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2475530318799072</pub-id><pub-id pub-id-type="pmcid">PMC6660180</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curtis</surname><given-names>JR</given-names></name><name name-style="western"><surname>Xie</surname><given-names>F</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C</given-names></name><name name-style="western"><surname>Saag</surname><given-names>KG</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Beukelman</surname><given-names>T</given-names></name><etal/></person-group><article-title>Changing trends in Opioid Use among patients with rheumatoid arthritis in the United States</article-title><source>Arthritis Rheumatol</source><year>2017</year><volume>69</volume><issue>9</issue><fpage>1733</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1002/art.40152</pub-id><pub-id pub-id-type="pmid">28635179</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Curtis JR, Xie F, Smith C, Saag KG, Chen L, Beukelman T, et al. Changing trends in Opioid Use among patients with rheumatoid arthritis in the United States. Arthritis Rheumatol. 2017;69(9):1733&#8211;40.<pub-id pub-id-type="pmid">28635179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.40152</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolkewitz</surname><given-names>M</given-names></name><name name-style="western"><surname>Beyersmann</surname><given-names>J</given-names></name><name name-style="western"><surname>Gastmeier</surname><given-names>P</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>M</given-names></name></person-group><article-title>Efficient risk set sampling when a time-dependent exposure is present: matching for time to exposure versus exposure density sampling</article-title><source>Methods Inf Med</source><year>2009</year><volume>48</volume><issue>5</issue><fpage>438</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.3414/ME9241</pub-id><pub-id pub-id-type="pmid">19657545</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Wolkewitz M, Beyersmann J, Gastmeier P, Schumacher M. Efficient risk set sampling when a time-dependent exposure is present: matching for time to exposure versus exposure density sampling. Methods Inf Med. 2009;48(5):438&#8211;43.<pub-id pub-id-type="pmid">19657545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3414/ME9241</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masnoon</surname><given-names>N</given-names></name><name name-style="western"><surname>Shakib</surname><given-names>S</given-names></name><name name-style="western"><surname>Kalisch-Ellett</surname><given-names>L</given-names></name><name name-style="western"><surname>Caughey</surname><given-names>GE</given-names></name></person-group><article-title>What is polypharmacy? A systematic review of definitions</article-title><source>BMC Geriatr</source><year>2017</year><volume>17</volume><issue>1</issue><fpage>230</fpage><pub-id pub-id-type="doi">10.1186/s12877-017-0621-2</pub-id><pub-id pub-id-type="pmid">29017448</pub-id><pub-id pub-id-type="pmcid">PMC5635569</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230.<pub-id pub-id-type="pmid">29017448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12877-017-0621-2</pub-id><pub-id pub-id-type="pmcid">PMC5635569</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pauly</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Michailidis</surname><given-names>L</given-names></name><name name-style="western"><surname>Kindred</surname><given-names>MG</given-names></name><name name-style="western"><surname>Flomenhoft</surname><given-names>D</given-names></name><name name-style="western"><surname>Lofwall</surname><given-names>MR</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Predictors of chronic opioid use in newly diagnosed Crohn&#8217;s Disease</article-title><source>Inflamm Bowel Dis</source><year>2017</year><volume>23</volume><issue>6</issue><fpage>1004</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1097/MIB.0000000000001087</pub-id><pub-id pub-id-type="pmid">28368908</pub-id><pub-id pub-id-type="pmcid">PMC5706777</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Pauly NJ, Michailidis L, Kindred MG, Flomenhoft D, Lofwall MR, Walsh SL, et al. Predictors of chronic opioid use in newly diagnosed Crohn&#8217;s Disease. Inflamm Bowel Dis. 2017;23(6):1004&#8211;10.<pub-id pub-id-type="pmid">28368908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MIB.0000000000001087</pub-id><pub-id pub-id-type="pmcid">PMC5706777</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noureldin</surname><given-names>M</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>PDR</given-names></name><name name-style="western"><surname>Govani</surname><given-names>SM</given-names></name><name name-style="western"><surname>Cohen-Mekelburg</surname><given-names>S</given-names></name><name name-style="western"><surname>Kenney</surname><given-names>BC</given-names></name><name name-style="western"><surname>Stidham</surname><given-names>RW</given-names></name><etal/></person-group><article-title>Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids</article-title><source>Aliment Pharmacol Ther</source><year>2019</year><volume>49</volume><issue>1</issue><fpage>74</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1111/apt.15023</pub-id><pub-id pub-id-type="pmid">30430615</pub-id><pub-id pub-id-type="pmcid">PMC6594920</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Noureldin M, Higgins PDR, Govani SM, Cohen-Mekelburg S, Kenney BC, Stidham RW, et al. Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids. Aliment Pharmacol Ther. 2019;49(1):74&#8211;83.<pub-id pub-id-type="pmid">30430615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/apt.15023</pub-id><pub-id pub-id-type="pmcid">PMC6594920</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhudy</surname><given-names>C</given-names></name><name name-style="western"><surname>Perry</surname><given-names>CL</given-names></name><name name-style="western"><surname>Singleton</surname><given-names>M</given-names></name><name name-style="western"><surname>Talbert</surname><given-names>J</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>TA</given-names></name></person-group><article-title>Chronic opioid use is associated with early biologic discontinuation in inflammatory bowel disease</article-title><source>Aliment Pharmacol Ther</source><year>2021</year><volume>53</volume><issue>6</issue><fpage>704</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1111/apt.16269</pub-id><pub-id pub-id-type="pmid">33497484</pub-id><pub-id pub-id-type="pmcid">PMC7897267</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Rhudy C, Perry CL, Singleton M, Talbert J, Barrett TA. Chronic opioid use is associated with early biologic discontinuation in inflammatory bowel disease. Aliment Pharmacol Ther. 2021;53(6):704&#8211;11.<pub-id pub-id-type="pmid">33497484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/apt.16269</pub-id><pub-id pub-id-type="pmcid">PMC7897267</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>YC</given-names></name><name name-style="western"><surname>Kremer</surname><given-names>J</given-names></name><name name-style="western"><surname>Guan</surname><given-names>H</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>J</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>DH</given-names></name></person-group><article-title>Chronic opioid use in rheumatoid arthritis: prevalence and predictors</article-title><source>Arthritis Rheumatol</source><year>2019</year><volume>71</volume><issue>5</issue><fpage>670</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1002/art.40789</pub-id><pub-id pub-id-type="pmid">30474933</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Lee YC, Kremer J, Guan H, Greenberg J, Solomon DH. Chronic opioid use in rheumatoid arthritis: prevalence and predictors. Arthritis Rheumatol. 2019;71(5):670&#8211;7.<pub-id pub-id-type="pmid">30474933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.40789</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szigethy</surname><given-names>EM</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>SM</given-names></name><name name-style="western"><surname>Ehrlich</surname><given-names>OG</given-names></name><name name-style="western"><surname>Heller</surname><given-names>CA</given-names></name><name name-style="western"><surname>Engel-Nitz</surname><given-names>NM</given-names></name><name name-style="western"><surname>Meadows</surname><given-names>P</given-names></name><etal/></person-group><article-title>Opioid Use Associated with higher costs among patients with inflammatory bowel disease</article-title><source>Crohns Colitis 360</source><year>2021</year><volume>3</volume><issue>2</issue><fpage>otab021</fpage><pub-id pub-id-type="doi">10.1093/crocol/otab021</pub-id><pub-id pub-id-type="pmid">36778940</pub-id><pub-id pub-id-type="pmcid">PMC9802349</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Szigethy EM, Murphy SM, Ehrlich OG, Heller CA, Engel-Nitz NM, Meadows P, et al. Opioid Use Associated with higher costs among patients with inflammatory bowel disease. Crohns Colitis 360. 2021;3(2):otab021.<pub-id pub-id-type="pmid">36778940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/crocol/otab021</pub-id><pub-id pub-id-type="pmcid">PMC9802349</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El Miedany</surname><given-names>Y</given-names></name><name name-style="western"><surname>Youssef</surname><given-names>S</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>I</given-names></name><name name-style="western"><surname>El Gaafary</surname><given-names>M</given-names></name></person-group><article-title>The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases</article-title><source>Am J Gastroenterol</source><year>2006</year><volume>101</volume><issue>2</issue><fpage>311</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2006.00384.x</pub-id><pub-id pub-id-type="pmid">16454836</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006;101(2):311&#8211;7.<pub-id pub-id-type="pmid">16454836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1572-0241.2006.00384.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sandborn</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Stenson</surname><given-names>WF</given-names></name><name name-style="western"><surname>Brynskov</surname><given-names>J</given-names></name><name name-style="western"><surname>Lorenz</surname><given-names>RG</given-names></name><name name-style="western"><surname>Steidle</surname><given-names>GM</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study</article-title><source>Clin Gastroenterol Hepatol</source><year>2006</year><volume>4</volume><issue>2</issue><fpage>203</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2005.12.002</pub-id><pub-id pub-id-type="pmid">16469681</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006;4(2):203&#8211;11.<pub-id pub-id-type="pmid">16469681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2005.12.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Miao XP, Li JS, Ouyang Q, Hu RW, Zhang Y, Li HY. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease. Cochrane Database Syst Rev. 2014(10):Cd007744.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD007744.pub2</pub-id><pub-id pub-id-type="pmcid">PMC11200115</pub-id><pub-id pub-id-type="pmid">25340915</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldsmith</surname><given-names>JR</given-names></name><name name-style="western"><surname>Sartor</surname><given-names>RB</given-names></name></person-group><article-title>Opioid toxicity in inflammatory bowel disease patients likely includes direct Enterocyte effects that Exacerbate Disease</article-title><source>Clin Gastroenterol Hepatol</source><year>2018</year><volume>16</volume><issue>10</issue><fpage>1679</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2018.05.017</pub-id><pub-id pub-id-type="pmid">30243353</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Goldsmith JR, Sartor RB. Opioid toxicity in inflammatory bowel disease patients likely includes direct Enterocyte effects that Exacerbate Disease. Clin Gastroenterol Hepatol. 2018;16(10):1679&#8211;80.<pub-id pub-id-type="pmid">30243353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2018.05.017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>HY</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>E</given-names></name><name name-style="western"><surname>Olmstead</surname><given-names>MC</given-names></name><name name-style="western"><surname>Burns</surname><given-names>LH</given-names></name></person-group><article-title>Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and gbetagamma signaling</article-title><source>Neuroscience</source><year>2005</year><volume>135</volume><issue>1</issue><fpage>247</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2005.06.003</pub-id><pub-id pub-id-type="pmid">16084657</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Wang HY, Friedman E, Olmstead MC, Burns LH. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and gbetagamma signaling. Neuroscience. 2005;135(1):247&#8211;61.<pub-id pub-id-type="pmid">16084657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2005.06.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Belvisi</surname><given-names>MG</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>DF</given-names></name></person-group><article-title>Modulation of neurogenic inflammation: novel approaches to inflammatory disease</article-title><source>Trends Pharmacol Sci</source><year>1990</year><volume>11</volume><issue>5</issue><fpage>185</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/0165-6147(90)90112-L</pub-id><pub-id pub-id-type="pmid">2248639</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Barnes PJ, Belvisi MG, Rogers DF. Modulation of neurogenic inflammation: novel approaches to inflammatory disease. Trends Pharmacol Sci. 1990;11(5):185&#8211;9.<pub-id pub-id-type="pmid">2248639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0165-6147(90)90112-l</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lakhan</surname><given-names>SE</given-names></name><name name-style="western"><surname>Kirchgessner</surname><given-names>A</given-names></name></person-group><article-title>Neuroinflammation in inflammatory bowel disease</article-title><source>J Neuroinflammation</source><year>2010</year><volume>7</volume><fpage>37</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-7-37</pub-id><pub-id pub-id-type="pmid">20615234</pub-id><pub-id pub-id-type="pmcid">PMC2909178</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Lakhan SE, Kirchgessner A. Neuroinflammation in inflammatory bowel disease. J Neuroinflammation. 2010;7:37.<pub-id pub-id-type="pmid">20615234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1742-2094-7-37</pub-id><pub-id pub-id-type="pmcid">PMC2909178</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szigethy</surname><given-names>E</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>M</given-names></name><name name-style="western"><surname>Drossman</surname><given-names>D</given-names></name></person-group><article-title>Narcotic bowel syndrome and opioid-induced constipation</article-title><source>Curr Gastroenterol Rep</source><year>2014</year><volume>16</volume><issue>10</issue><fpage>410</fpage><pub-id pub-id-type="doi">10.1007/s11894-014-0410-4</pub-id><pub-id pub-id-type="pmid">25183577</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Szigethy E, Schwartz M, Drossman D. Narcotic bowel syndrome and opioid-induced constipation. Curr Gastroenterol Rep. 2014;16(10):410.<pub-id pub-id-type="pmid">25183577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11894-014-0410-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vijayan</surname><given-names>V</given-names></name><name name-style="western"><surname>Moran</surname><given-names>R</given-names></name><name name-style="western"><surname>Elder</surname><given-names>ME</given-names></name><name name-style="western"><surname>Sukumaran</surname><given-names>S</given-names></name></person-group><article-title>Acute-onset opioid-induced hyperalgesia in a child with juvenile idiopathic arthritis</article-title><source>J Clin Rheumatol</source><year>2012</year><volume>18</volume><issue>7</issue><fpage>349</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1097/RHU.0b013e31826d2663</pub-id><pub-id pub-id-type="pmid">23047535</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Vijayan V, Moran R, Elder ME, Sukumaran S. Acute-onset opioid-induced hyperalgesia in a child with juvenile idiopathic arthritis. J Clin Rheumatol. 2012;18(7):349&#8211;51.<pub-id pub-id-type="pmid">23047535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/RHU.0b013e31826d2663</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>EL</given-names></name><name name-style="western"><surname>Kochar</surname><given-names>B</given-names></name><name name-style="western"><surname>Long</surname><given-names>MD</given-names></name><name name-style="western"><surname>Kappelman</surname><given-names>MD</given-names></name><name name-style="western"><surname>Martin</surname><given-names>CF</given-names></name><name name-style="western"><surname>Korzenik</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Modifiable risk factors for Hospital Readmission among patients with inflammatory bowel disease in a Nationwide Database</article-title><source>Inflamm Bowel Dis</source><year>2017</year><volume>23</volume><issue>6</issue><fpage>875</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1097/MIB.0000000000001121</pub-id><pub-id pub-id-type="pmid">28426473</pub-id><pub-id pub-id-type="pmcid">PMC5512697</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Barnes EL, Kochar B, Long MD, Kappelman MD, Martin CF, Korzenik JR, et al. Modifiable risk factors for Hospital Readmission among patients with inflammatory bowel disease in a Nationwide Database. Inflamm Bowel Dis. 2017;23(6):875&#8211;81.<pub-id pub-id-type="pmid">28426473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MIB.0000000000001121</pub-id><pub-id pub-id-type="pmcid">PMC5512697</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szigethy</surname><given-names>E</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>SM</given-names></name><name name-style="western"><surname>Ehrlich</surname><given-names>OG</given-names></name><name name-style="western"><surname>Engel-Nitz</surname><given-names>NM</given-names></name><name name-style="western"><surname>Heller</surname><given-names>CA</given-names></name><name name-style="western"><surname>Henrichsen</surname><given-names>K</given-names></name><etal/></person-group><source>Mental Health Costs Inflamm Bowel Dis Inflamm Bowel Dis</source><year>2021</year><volume>27</volume><issue>1</issue><fpage>40</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">32095835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ibd/izaa030</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Szigethy E, Murphy SM, Ehrlich OG, Engel-Nitz NM, Heller CA, Henrichsen K, et al. Mental Health Costs Inflamm Bowel Dis Inflamm Bowel Dis. 2021;27(1):40&#8211;8.<pub-id pub-id-type="pmid">32095835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ibd/izaa030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cross</surname><given-names>RK</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>KT</given-names></name><name name-style="western"><surname>Binion</surname><given-names>DG</given-names></name></person-group><article-title>Polypharmacy and Crohn&#8217;s disease</article-title><source>Aliment Pharmacol Ther</source><year>2005</year><volume>21</volume><issue>10</issue><fpage>1211</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2005.02429.x</pub-id><pub-id pub-id-type="pmid">15882241</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Cross RK, Wilson KT, Binion DG. Polypharmacy and Crohn&#8217;s disease. Aliment Pharmacol Ther. 2005;21(10):1211&#8211;6.<pub-id pub-id-type="pmid">15882241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2036.2005.02429.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buckley</surname><given-names>JP</given-names></name><name name-style="western"><surname>Kappelman</surname><given-names>MD</given-names></name><name name-style="western"><surname>Allen</surname><given-names>JK</given-names></name><name name-style="western"><surname>Van Meter</surname><given-names>SA</given-names></name><name name-style="western"><surname>Cook</surname><given-names>SF</given-names></name></person-group><article-title>The burden of comedication among patients with inflammatory bowel disease</article-title><source>Inflamm Bowel Dis</source><year>2013</year><volume>19</volume><issue>13</issue><fpage>2725</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1097/01.MIB.0000435442.07237.a4</pub-id><pub-id pub-id-type="pmid">24216689</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Buckley JP, Kappelman MD, Allen JK, Van Meter SA, Cook SF. The burden of comedication among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(13):2725&#8211;36.<pub-id pub-id-type="pmid">24216689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.MIB.0000435442.07237.a4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cross</surname><given-names>RK</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>KT</given-names></name><name name-style="western"><surname>Binion</surname><given-names>DG</given-names></name></person-group><article-title>Narcotic use in patients with Crohn&#8217;s disease</article-title><source>Am J Gastroenterol</source><year>2005</year><volume>100</volume><issue>10</issue><fpage>2225</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2005.00256.x</pub-id><pub-id pub-id-type="pmid">16181373</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Cross RK, Wilson KT, Binion DG. Narcotic use in patients with Crohn&#8217;s disease. Am J Gastroenterol. 2005;100(10):2225&#8211;9.<pub-id pub-id-type="pmid">16181373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1572-0241.2005.00256.x</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>